TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10588412
Drug: Sustained outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained outpatient commitment with higher intensity of outpatient treatment
Study: 8537594
Drug: A.G.E. dementia
Approvals — FDA: no, EMA: no, PMDA: no
Description: A.G.E. dementia care program
Study: 24611484
Drug: UP446 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP446 (500 mg/day)
Study: 24611484
Drug: naproxen (440
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (440 mg/day)
Study: 17239062
Drug: Community-based stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based stroke prevention programme (eight weekly two-hour sessions)
Study: 9585772
Drug: Broad spectrum
Normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Broad spectrum antimicrobial therapy and operation
Study: 7896992
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 mg) available to all participants
Study: 28541285
Drug: Pharmacological challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological challenge of opioid receptor function
Study: 23637069
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy programme for care home staff to increase activity provision
Study: 19594087
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g CHO in 400 ml of water
Study: 19594087
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g aspartam in 100 ml of water (Control)
Study: 15487740
Drug: Functional-imaging-weighted equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional-imaging-weighted equivalent uniform dose (fEUD) calculation using FDG-PET activity as a surrogate for tumor cell density
Study: 15487740
Drug: Equivalent uniform
Normalized name: Eugenia uniflora whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent uniform dose (EUD) calculation assuming uniform tumor cell density
Study: 11598557
Drug: Misoprostol with
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol with oxytocin infusion
Study: 7700063
Drug: Cilazapril 1-5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1-5 mg once daily for 12 weeks
Study: 7700063
Drug: Cilazapril 0.5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 0.5-15 mg once daily
Study: 7700063
Drug: Cilazapril therapy
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril therapy
Study: 3038254
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg daily for 6 months
Study: 25639570
Drug: Present-Centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-Centered therapy (PCT)
Study: 25639570
Drug: High treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High treatment responders (collapsed across treatments)
Study: 25639570
Drug: High treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High treatment responders (mid-treatment)
Study: 25639570
Drug: Thoughts of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoughts of incompetence (high treatment responders)
Study: 25639570
Drug: Thoughts of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoughts of a dangerous world (high treatment responders)
Study: 25639570
Drug: Script-associated cortisol
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Script-associated cortisol response prior to treatment and reductions in thoughts of incompetence
Study: 17057622
Drug: Standard monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monitoring including hormone assays and ultrasound
Study: 12419788
Drug: High-fiber supplement
Normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber supplement (13.5 g/day)
Study: 12419788
Drug: Low-fiber supplement
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber supplement (2.0 g/day)
Study: 10321445
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy change due to inadequate blood pressure control
Study: 10321445
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy change due to adverse effects
Study: 10321445
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy change due to patient dissatisfaction
Study: 10321445
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy change due to non-compliance
Study: 10321445
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy change due to cost
Study: 27644137
Drug: ω-3-rich enteral
Normalized name: budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ω-3-rich enteral nutrition (900 mg of ω-3 fatty acids)
Study: 27644137
Drug: ω-3-poor enteral
Normalized name: budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ω-3-poor enteral nutrition (250 mg of ω-3 fatty acids)
Study: 23359310
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (4.5 mg/day)
Study: 21062392
Drug: Naftopidil 75
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 75 mg/day for 6 weeks
Study: 19926556
Drug: Pharmacist‐provided intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist‐provided intervention to improve heart failure medication adherence
Study: 10374274
Drug: Fluconazole (Flu)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (Flu) 200-400 mg daily for 1-8 weeks
Study: 10374274
Drug: Ketoconazole (Keto)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (Keto) 400 mg daily for 1-8 weeks
Study: 10374274
Drug: Fluconazole (Flu)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (Flu) in open trial (150 mg single dose for fungal vaginitis)
Study: 3330526
Drug: AQ‐A 39
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQ‐A 39 (falipamil), 2 mg kg‐1
Study: 3330526
Drug: Propranolol, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 0.1 mg kg‐1
Study: 10895746
Drug: Triamcinolone 40
Normalized name: TRIAMCINOLONE 40MG/ML INJ,SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone 40 mg
Study: 31164277
Drug: 3-weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly cisplatin
Study: 31364232
Drug: L-NMMA +
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA + Teduglutide
Study: 31364232
Drug: L-NMMA +
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA + Placebo
Study: 25769495
Drug: Tumour necrosis
Normalized name: Tumour necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour necrosis factor inhibitor strategy
Study: 25769495
Drug: Combined disease
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined disease modifying drug strategy
Study: 23394263
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (ertapenem 1 g per day for 3 days, followed by oral levofloxacin 500 mg per day and metronidazole 1.5 g per day for 7 days)
Study: 17154642
Drug: Methotrexate therapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate therapy (starting dose of 10-15 mg/m2/week orally, increased to 15-20 mg/m2/week parenterally)
Study: 17154642
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with methotrexate and an NSAID
Study: 17154642
Drug: Daily folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily folate supplementation
Study: 12580112
Drug: Effervescent tablet
Normalized name: Pain Relief Effervescent Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablet of potassium chloride (2 g)
Study: 12580112
Drug: Common tablet
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common tablet of potassium chloride (2 g)
Study: 9240183
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 2% lignocaine gel for 25 min
Study: 9240183
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 2% lignocaine gel for 15 min
Study: 9240183
Drug: Plain lubricating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain lubricating gel for 5 min
Study: 9240183
Drug: Plain lubricating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain lubricating gel for 25 min
Study: 9240183
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 2% lignocaine gel for 5 min
Study: 31987331
Drug: Supplemental CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental CoQ10 (300 mg/kg)
Study: 31987331
Drug: Supplemental CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental CoQ10 (600 mg/kg)
Study: 31987331
Drug: Supplemental CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental CoQ10 (900 mg/kg)
Study: 15377061
Drug: Combination dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination dietary supplement
Study: 8046120
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg capsules)
Study: 8046120
Drug: Nitrendipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (5 mg from vial)
Study: 29483185
Drug: Basal-Bolus Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-Bolus Insulin
Study: 22739369
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplements (5 g/d, 2 g EPA, 1 g DHA)
Study: 22739369
Drug: Corn/soy oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn/soy oil (PL) (5 g/d)
Study: 20604814
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with 80 mg Tokyo strain BCG instillation once weekly for eight consecutive weeks.
Study: 20604814
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with four additional BCG instillations after achieving CR.
Study: 20604814
Drug: Observation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation group (control) after induction therapy.
Study: 20604814
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with BCG.
Study: 20604814
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with BCG.
Study: 20604814
Drug: Induction and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and maintenance therapy with BCG.
Study: 16554456
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/d) for 18 days
Study: 16554456
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/d) coadministered in the last 4 study days
Study: 16554456
Drug: Paroxetine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine and Aspirin combination
Study: 10670114
Drug: rocuronium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.05 mg/kg
Study: 10670114
Drug: vecuronium 0.007
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.007 mg/kg
Study: 9078354
Drug: IVIg (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (500 mg/kg/month)
Study: 1856146
Drug: Netilmicin once
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin once daily (6.6 mg/kg)
Study: 1856146
Drug: Amikacin once
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin once daily (14.5 mg/kg)
Study: 1856146
Drug: Netilmicin thrice
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin thrice daily (tid)
Study: 1856146
Drug: Netilmicin twice
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin twice daily (bd)
Study: 1856146
Drug: Amikacin twice
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin twice daily (bd)
Study: 24698485
Drug: Darunavir 800
Normalized name: darunavir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir 800 mg plus ritonavir 100 mg once daily
Study: 19317821
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (s.c.)
Study: 15258698
Drug: Oral cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cisplatin (10‐30 mg/m2)
Study: 15258698
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin (30‐min infusions)
Study: 15258698
Drug: Oral cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cisplatin
Study: 10561263
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated radiation therapy (ACC HFX RT) with 54 Gy in 36 fractions over 18 treatment days plus concurrent daily carboplatin/etoposide (CE) (group 1, n = 55)
Study: 10561263
Drug: Cisplatin/etoposide (PE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/etoposide (PE) chemotherapy alone (group 2, n = 54)
Study: 10150495
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 micrograms) twice daily with HFA134a
Study: 10150495
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) (250 micrograms) twice daily with HFA134a
Study: 2285609
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 30 mg/day + Bromocriptine (B) 5 mg/day
Study: 2285609
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 30 mg/day + Placebo
Study: 7029648
Drug: PGE2 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 0.04 mg four times daily
Study: 7029648
Drug: PGE2 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 0.25 mg four times daily
Study: 7029648
Drug: PGE2 0.5
Normalized name: PGE2 0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 0.5 mg four times daily
Study: 7029648
Drug: ASA (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (650 mg four times daily)
Study: 30280324
Drug: Whitening strips
Normalized name: Teeth Whitener Dental Film [LUMINEUX WHITENING STRIPS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitening strips (White Strips, Oral-b)
Study: 21936957
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of skill-building and price reductions
Study: 18347178
Drug: Tamoxifen-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen-based therapy (ABCSG Trial 05)
Study: 18347178
Drug: Tamoxifen-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen-based therapy (ABCSG Trial 06)
Study: 10761165
Drug: OROS (methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS (methylphenidate HCl) 18 mg qd
Study: 10761165
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) methylphenidate 20 mg qd
Study: 10761165
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation (three 5 mg doses every 4 hours)
Study: 8598756
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐oestradiol 200 micrograms daily for 3 months, then 3 months with added cyclical dydrogesterone 10mg daily for 12 days each month
Study: 8598756
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches and tablets according to the same regimen
Study: 3903070
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (1000 mg bolus and 1000 mg daily for 10 days)
Study: 3903070
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose methylprednisolone (100 mg bolus and 100 mg daily for 10 days)
Study: 23146983
Drug: Citalopram, 20
Normalized name: Escitalopram, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram, 20 mg/d for 3 months
Study: 18819472
Drug: Oral tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tacrolimus
Study: 15497661
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Osalen 10 mg tablets)
Study: 15497667
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (originator product)
Study: 8318320
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% infused at 5 ml h‐1
Study: 26493601
Drug: Family-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive-behavioral therapy for chronic pain
Study: 18503493
Drug: Perceived barriers
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived barriers to physical activity (e.g., poor health, fear, negative experiences, lack of knowledge)
Study: 9689428
Drug: Ranitidine 4
Normalized name: ranitidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 4 x 150 mg or tetracycline 4 x 500 mg or metronidazole 3 x 250 mg for 2 weeks
Study: 2543309
Drug: Syo‐saiko‐to (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syo‐saiko‐to (7.5 g/day)
Study: 2543309
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine (control group)
Study: 30738342
Drug: Expectation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation of teaching with unlimited motor preparation
Study: 30738342
Drug: Expectation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation of teaching with limited motor preparation
Study: 30738342
Drug: Expectation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation of being tested with unlimited motor preparation
Study: 30738342
Drug: Expectation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation of being tested with limited motor preparation
Study: 26022817
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg, n = 519
Study: 23651076
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (S)
Study: 23651076
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral sucrose and facilitated tucking (SFT)
Study: 19162420
Drug: Non-olanzapine antipsychotic
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-olanzapine antipsychotic
Study: 15231903
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy with succimer
Study: 8150546
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 10 mg) once daily
Study: 8150546
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (25 to 100 mg) daily
Study: 8150546
Drug: Amlodipine-atenolol combination
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-atenolol combination therapy
Study: 8150546
Drug: HCTZ-atenolol combination
Normalized name: amiloride / atenolol / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ-atenolol combination therapy
Study: 28857388
Drug: Metformin extended-release
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin extended-release (XR) 2000 mg once daily
Study: 28857388
Drug: Metformin immediate-release
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin immediate-release (IR) 1000 mg twice daily
Study: 18585701
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg/day
Study: 12814444
Drug: Moxonidine sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine sustained release (1.5 mg o.d.)
Study: 6342837
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg i.v. + 200 mg/day) for 90 days